Needham Reiterates Buy on Neumora Therapeutics, Maintains $8 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 81.9%

Neg 0% Neu 81.9% Pos 0%

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and maintains $8 price target.

Comments

No comments yet. Be the first!